EUVIMEDOpdag EUVIMED
Crossref

Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer

Sun Ruixin, Liu Yifan, Sun Yansha, Zhou Min, Dong Yiwei, Hu Xiaoli, Shi Bizhi, Jiang Hua, Li Zonghai

British Journal of Pharmacology · 2024-11 · 181 (22) · 4628-4646

DOI: 10.1111/bph.16505 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2024-08-11. Written by Sun Ruixin and 8 co-authors. Institution: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shan…. Major MEDLINE topics: Pancreatic Neoplasms, Receptors, Chimeric Antigen, T-Lymphocytes. Cited 24 times so far (Crossref); 68 references. Funded by: "Gan Quan Xin Xing" talent training program of Shanghai Tongji Hospital, Shanghai "Rising Stars of Medical Talents" Youth Development Program-Clinical Laboratory Practitioner Program, Shanghai Oriental Talent Youth Project.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Although our previous data indicated that claudin 18 isoform 2 (CLDN18.2)‐targeted chimeric antigen receptor (CAR) T cells displayed remarkable clinical efficacy in CLDN18.2‐positive gastric cancer, their efficacy is limited in pancreatic ductal adenocarcinoma (PDAC). The tumour microenvironment (TME) is one of the main obstacles to the efficacy of CAR‐T and remodelling the TME may be a possible way to overcome this obstacle. The TME of PDAC is characterized by abundant cancer‐related fibroblasts (CAFs), which hinder the infiltration and function of CLDN18.2‐targeted CAR‐T cells. The expression of fibroblast activation protein alpha (FAP) is an important feature of active CAFs, providing potential targets for eliminating CAFs. Experimental Approach In this study, we generated 10 FAP/CLDN 18.2 dual‐targeted CAR‐T cells and evaluated their anti‐tumour ability in vitro and in vivo. Key Results Compared with conventional CAR‐T cells, some dual‐targeted CAR‐T cells showed improved therapeutic effects in mouse pancreatic cancers. Further, dual‐targeted CAR‐T cells with better anti‐tumour effect could suppress the recruitment of myeloid‐derived suppressor cells (MDSCs) to improve the immunosuppressive TME, which contributes to the survival of CD8 + T cells. Moreover, dual‐targeted CAR‐T cells reduced the exhaustion of T cells in transforming TGF‐β dependent manner. Conclusion and Implications The dual‐targeted CAR‐T cells obtained enhancement of T effector function, inhibition of T cell exhaustion, and improvement of tumour microenvironment. Our findings provide a theoretical rationale for dual‐targeted FAP/CLDN 18.2 CAR‐T cells therapy in PDAC.

Subjects

MeSH terms (MEDLINE)

Pancreatic NeoplasmsReceptors, Chimeric AntigenT-LymphocytesAnimalsMiceHumansTumor MicroenvironmentCell Line, TumorImmunotherapy, AdoptiveCarcinoma, Pancreatic DuctalClaudinsT-Cell ExhaustionMembrane ProteinsEndopeptidasesFibroblast Activation Protein Alpha

Author keywords

T cell exhaustioncancer‐associated fibroblastsdual‐targeted CAR‐Tpancreatic cancer

Substances

Receptors, Chimeric AntigenClaudinsMembrane ProteinsEndopeptidasesFibroblast Activation Protein Alpha

Authors and institutions

  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Department of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
  • CARsgen Therapeutics, Shanghai, China.

Funding

  • "Gan Quan Xin Xing" talent training program of Shanghai Tongji Hospital
  • Shanghai "Rising Stars of Medical Talents" Youth Development Program-Clinical Laboratory Practitioner Program
  • Shanghai Oriental Talent Youth Project
  • Shanghai Municipal Health and Family Planning Commission
  • National Natural Science Foundation of China

Cite

APA

Ruixin, S., Yifan, L., Yansha, S., Min, Z., Yiwei, D., Xiaoli, H., Bizhi, S., Hua, J., & Zonghai, L. (2024). Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer. British Journal of Pharmacology, 181(22), 4628-4646. https://doi.org/10.1111/bph.16505

Vancouver

Ruixin S, Yifan L, Yansha S, Min Z, Yiwei D, Xiaoli H, et al. Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer. British Journal of Pharmacology. 2024;181(22):4628-4646. doi:10.1111/bph.16505

BibTeX
@article{Ruixin2024,
  author = {Ruixin, Sun and Yifan, Liu and Yansha, Sun and Min, Zhou and Yiwei, Dong and Xiaoli, Hu and Bizhi, Shi and Hua, Jiang and Zonghai, Li},
  title = {Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {22},
  pages = {4628--4646},
  doi = {10.1111/bph.16505}
}
Start for free →